FDA Approves Pfizer and Moderna’s New Formulation COVID-19 Vaccines
- Painkillers and Contraceptives: Risky Combination for Women
- IAEA Shutdown Soon Due to Japan Nuclear Water and Austrian Submarines?
- Baby Crying Elicits Oxytocin Release in Mothers
- mRNA Vaccine Targeting Bacteria to Prevent Lyme Disease from Tick Bites
- Aspartame: Memory & Learning Deficits and Transgenerational Effects
- Mysterious Circular RNA Linked to Alzheimer’s and Parkinson’s Diseases
FDA Approves Pfizer and Moderna’s New Formulation COVID-19 Vaccines, No Longer Utilizing Original Strain
- Nearly 300 People Food Poisoning in Japanese 130-Year Restaurant
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
FDA Approves Pfizer and Moderna’s New Formulation COVID-19 Vaccines, No Longer Utilizing Original Strain
The U.S. Food and Drug Administration (FDA) has granted approval for Pfizer and Moderna’s newly formulated COVID-19 vaccines.
Unlike the booster shots previously released, these vaccines are not composed of components from the original strain of the virus that circulated in 2020.
According to The New York Times, in line with the FDA’s recommendation in June, this is a monovalent vaccine targeting the omicron subvariant.
The new vaccine is specifically designed to combat the omicron variant XBB.1.5, which became the predominant strain of the virus in certain regions of the United States last winter and is closely related to EG.5. According to CDC data, EG.5 currently accounts for 21.5% of cases.
The chart illustrates the prevalence of COVID-19 virus variants based on CDC data, reported as of August and estimated into September.
The National SARS-CoV-2 Genomic Surveillance Program sequences a nationally representative collection of clinical respiratory specimens to identify and monitor the spread of variants.
Image: Centers for Disease Control and Prevention
While the FDA has authorized the vaccine for individuals aged 12 and older, it has granted emergency use authorization for children aged 6 months to 11 years.
Following this update, the previous booster shots from Moderna and Pfizer are no longer authorized for use in the United States.
The FDA has noted that the updated vaccine is “anticipated to provide robust protection against the currently circulating variants of COVID-19” and added that the vaccine’s “components” may need to be updated annually, similar to what we see with influenza vaccines.
The Centers for Disease Control and Prevention (CDC) is scheduled to discuss vaccine recommendations on Sep 08.
If the CDC issues recommendations tomorrow, the vaccines could be made available to the public by the end of this week.
FDA Approves Pfizer and Moderna’s New Formulation COVID-19 Vaccines, No Longer Utilizing Original Strain
(source:internet, reference only)
Disclaimer of medicaltrend.org
